High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: To study the feasibility and activity of two courses of high-dose chemotherapy (HDCT) in patients with osteosarcoma in metastatic relapse. PATIENTS AND METHODS: Patients with high-grade osteosarcoma in metastatic relapse (multiple metastases or solitary metastasis at intervals of less than 30 months) were eligible for study. High-dose chemotherapy consisted of carboplatin and etoposide followed by stem-cell rescue. A second course was planned 4 to 6 weeks after the first. Surgery was performed before or after HDCT. RESULTS: Thirty-two patients were enrolled onto the study. At the end of the treatment, 25 patients were in complete remission (CR), six were alive with disease progression, and one died of toxicity. At present, 14 patients are alive with a median survival time of 23 months from study entry: four are in first CR, three are in second CR, and one is in fourth CR. Six patients are alive with disease. Eighteen patients (56%) died: 17 of disease and one of toxicity. Transplantation-related mortality was 3.1%. The relapse or progression disease rate was 84.4%. The 3-year overall survival rate is 20% and the 3-year disease-free survival rate is 12%. CONCLUSION: HDCT combined with surgery is feasible and can induce CR in a large portion of patients. Two points, however, need to be considered: only patients who are chemosensitive to induction treatment can obtain CR after HDCT, and the length of remission is short, because most patients relapse. Thus novel strategies are needed to maintain the remission status or to treat patients who do not respond to induction treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meyers, P. A., Gorlick, R., Heller, G., Casper, E., Lane, J., Huvos, A. G., & Healey, J. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2452 · Cited by 294 · cited 1×
“This improvement is attributed to (1) the effect of preoperative chemotherapy,(1-4) (2) the introduction of aggressive chemotherapy with various combinations of high-dose methotrexate, doxorubicin, cisplatinum, and ifosfamide,(5-8) (3) the identification of the relationship of dose-response between methotrexate, doxor…”
Background
Cited by
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationPedrazzoli, P., Ledermann, J. A., Lotz, J.-P., Leyvraz, S., Aglietta, M., Rosti, G., Champion, K. M., Secondino, S., Selle, F., Ketterer, N., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl044 · Cited by 655
Self-citationPrimary bone osteosarcoma in the pediatric age: State of the art
Longhi, A., Errani, C., De Paolis, M., Mercuri, M., & Bacci, G. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.05.005 · Cited by 631
Self-citationFerrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Self-citationLilienthal, I., & Herold, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186885 · Cited by 283
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Penel-Page, M., Ray-Coquard, I., Larcade, J., Girodet, M., Bouclier, L., Rogasik, M., Corradini, N., Entz-Werle, N., Brugieres, L., Domont, J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1894-5 · Cited by 32
“Except for muramyl tripeptide (L-MTP-PE) which demonstrated an improvement of median time to relapse from 4,5 months to 9 months in a phase II trial [6], recently tested drugs (etoposide, carboplatine, gemcitabine, high dose chemotherapy [7], ecteinascidin [8], samarium [9]) failed to improve long-term survival of the…”
BackgroundManagement of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
Metadata
- Authors
- Fagioli, F., Aglietta, M., Tienghi, A., Ferrari, S., Brach del Prever, A., Vassallo, E., Palmero, A., Biasin, E., Bacci, G., Picci, P., & Madon, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-04-15
- Volume
- 20
- Issue
- 8
- Pages
- 2150-2156
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161522889
- Cited by
- 133
- References
- 1
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.